Global Macro Trading Journal

Discussion in 'Journals' started by Daal, Feb 25, 2011.

  1. Daal

    Daal

    The NYT pieces bashing VRX were taking one or 2 drugs out of a huge portfolio, looking at gross price increases and generalizing the entire company based on that. thats a mistake
     
    #5531     Nov 2, 2015
  2. newwurldmn

    newwurldmn

    It's possible. Ackman mentioned that he has spoken to Munger about it, but he didn't comment on Mungers specific qualms. My only concern would be that Sequioa and other deep value investors either are friends or are disciples of Munger/Buffet. So it makes it harder for a deep value guy to go against the view.

    Munger did say that Valeant is a very Buffet-esque company: no glitz of a typical biotech pharma.

    I am also long through short upside puts and some stock.
     
    #5532     Nov 2, 2015
  3. Daal

    Daal

    Munger is a great investor, however, ins't the success of Berkshire, according to Buffett, largely been driven by buying companies with big moats who have pricing power? So by definition they want companies who can raise prices more than their competitors. As I said before, if someone have studies who can prove that raising prices in sectors that a price inelastic (like healthcare) at will, increase their profits and then decrease those prices when the inelasticity starts to lose its effect. And that this is strategy is sustainable in the long-term (hard to be copied by others and hence monopolistic in nature), then the government definetly needs to ban it. Its not the job of VRX to do that though, they are playing by the rules
     
    #5533     Nov 2, 2015
  4. Daal

    Daal

    If anything, the outcry against that shows that the strategy is not sustainable. There is the loss of brand value associated with the strategy (which can be calculated down to a monetary value). That loss of brand value (both of the company and its products) and popularity is an extra cost associated with the strategy which decreases its profits. Thats why VRX and many others are backing down from that, as they should.
     
    #5534     Nov 2, 2015
  5. newwurldmn

    newwurldmn

    Ha. that is very true.
     
    #5535     Nov 2, 2015
  6. newwurldmn

    newwurldmn

    The valeant brand name is meaningless - the drug brand names are what matter. And that hasn't changed.

    It looks like Citron is admitting they are wrong in their Enron claims by saying this is their last report.
     
    #5536     Nov 2, 2015
  7. Daal

    Daal

    Another thing with VRX is that because I'm a day trader, if some news comes out intraday (or even when the markets are closed), I'm likely to short the stock as a hedge or even take a directional short on it. So this makes the stock a bit less risky to me because I can protect myself if things change. I don't want people getting in and them getting hurt when they don't react to an event so keep that in mind.
     
    #5537     Nov 3, 2015
  8. Daal

    Daal

    I'm likely to reduce my VRX today if the stock opens up. I'm finding myself taking too much time of my day to research this stuff again. If I take this down from 4% to 2%, I believe I will be able to ignore the noise and hold it more. Its a very volatile stock anyway, so its probably more appropriate

    I also plan to buy the brazilian stock index position I mentioned earlier. Initially a 2% position and I will scale into all the to 5%
     
    #5538     Nov 3, 2015
  9. Daal

    Daal

    Gonna let this thing squeeze shorts a bit then lighten up some
     
    #5539     Nov 3, 2015
  10. Daal

    Daal

    This gap up was good enough. I cut back to a bit under 2% position. I think thats conservative but its a complex company that requires a lot of work, so I can't justify being all agressive
     
    #5540     Nov 3, 2015